Information Provided By: 
Fly News Breaks for May 20, 2015
SRPT
May 20, 2015 | 08:40 EDT
After the FDA instructed Sarpeta to begin submission of its NDA for eteplirsen on a rolling basis, JMP Securities remains cautious on the drug's approvability, due to the small dataset of the study on which Sarepta is relying and the fact that the drug failed a prior Phase 3 study. The firm sees a 50% chance that the drug will succeed, up from its prior 30% estimate. It keeps a Market Perform rating on the shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
